Zhenya Lindgardt Sells 21,158 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 21,158 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total transaction of $66,647.70. Following the transaction, the chief executive officer owned 811,136 shares of the company’s stock, valued at approximately $2,555,078.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sera Prognostics Stock Performance

SERA opened at $3.07 on Thursday. The firm has a market cap of $115.65 million, a P/E ratio of -3.61 and a beta of 1.00. The firm has a 50-day moving average of $2.79 and a 200 day moving average of $2.88. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. Equities research analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Sera Prognostics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th.

Hedge Funds Weigh In On Sera Prognostics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AWM Investment Company Inc. boosted its position in Sera Prognostics by 48.1% during the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company’s stock worth $3,190,000 after purchasing an additional 281,703 shares during the period. Aberdeen Group plc bought a new position in Sera Prognostics during the first quarter worth about $4,563,000. Ghisallo Capital Management LLC bought a new position in Sera Prognostics during the first quarter worth about $368,000. Perkins Capital Management Inc. bought a new position in Sera Prognostics during the first quarter worth about $522,000. Finally, Deutsche Bank AG boosted its position in Sera Prognostics by 4,743.6% during the fourth quarter. Deutsche Bank AG now owns 35,358 shares of the company’s stock worth $288,000 after purchasing an additional 34,628 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.